Background. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved updated dose recommendations for intravenous colistin in patients with various degrees of renal function. We assessed the recommendations in relation to their ability to achieve clinically relevant plasma colistin concentrations.
Colistin, administered as its inactive prodrug colistimethate, first became available for clinical use in the 1950s [1] [2] [3] [4] . After several years, colistimethate was largely shelved because of concerns about the potential for adverse effects, particularly nephrotoxicity [3, 5] . It was resurrected in the 1990s for use in cystic fibrosis patients and, more recently, in other types of patients including the critically ill. Over the last decade the pharmacological and clinical knowledge of colistin has increased significantly.
The ratio of the area under the unbound colistin plasma concentration vs time curve across a day to the minimum inhibitory concentration ( fAUC/MIC) is the pharmacokinetic/ pharmacodynamic (PK/PD) index linked to antibacterial effect [6] . Against 3 strains each of Pseudomonas aeruginosa and Acinetobacter baumannii in the mouse thigh infection model, an fAUC/MIC of 12 corresponded to the approximate average 2-log bacterial kill target for both species. Lung infection was less responsive. Against P. aeruginosa, an average fAUC/MIC of approximately 48 was required for 1-log bacterial kill, while this level of killing was seen in only 1 of 3 strains of A. baumannii [6] . In translating such preclinical targets to the clinic setting, it is necessary to recognize that colistin is approximately 50% unbound in human plasma, including in critically ill patients [6] . The fAUC is commonly expressed as the average steady-state plasma concentration (ie, fAUC divided by 24 hours). Thus, fAUC/MIC of 12 and 48 correspond to average steady-state total (ie, bound plus unbound) plasma colistin concentrations (C ss,avg ) of 1 and 4 mg/L in a patient for an organism having an MIC of 1 mg/L. Recent toxicodynamic analyses, including data from the same 162 patients, considered in the current work, indicate that the risk of nephrotoxicity in patients increases with plasma colistin concentration, especially as colistin C ss,avg exceeds approximately 2.5 mg/L [7, 8] , and in patients with creatinine clearance >80 mL/min [8] . Clearly, there is substantial overlap in the plasma colistin exposure associated with antibacterial effect and risk of developing nephrotoxicity. Therefore, colistin has a narrow therapeutic window [9] [10] [11] .
The original product labels for colistimethate were based on rudimentary pharmacological information from many decades ago [3, 12] . Consequently, the guidance to clinicians across a range of areas, including the very important aspect of selection of dosage regimens for individual patients, remained largely unchanged for several decades [13] . Coincident with the resurgence in clinical use and new pharmacological knowledge that has emerged from research studies conducted over the last 10-15 years, product information for colistimethate has begun to change on both sides of the Atlantic Ocean.
In September 2013, the European Commission (EC) requested the European Medicines Agency (EMA) to undertake a review of the safety and effectiveness of colistimethate products. The EC accepted the recommendations from the review in December 2014 [14] . The outcome is the requirement for product information, including the dosage recommendations section, to be updated and harmonized across the member countries of the European Union. In a less extensively described process, the US Food and Drug Administration (FDA) approved changes to the dosage and administration section of the product label for colistimethate in the United States [15] . The FDA had requested pharmaceutical companies to make changes, but it is unclear whether relatively recently acquired pharmacological findings informed the changes. The recently updated EMA-and FDAapproved daily maintenance dose suggestions for intravenous colistimethate are summarized in Table 1 . For both regulatory authorities, the suggestions are based on renal function because the overall disposition of colistimethate and the colistin formed from it are influenced by kidney function [16] .
The first aim of our study was to evaluate the recently updated EMA-and FDA-approved colistimethate daily maintenance dose suggestions for patients with a wide range of renal function in regard to the plasma colistin concentrations achieved. The second aim was to compare the relative performance of the 2 sets of dosing suggestions.
PATIENTS AND METHODS

Patients and Ethics
For our analyses, we used data from a multinational, multicenter study on the population PK of colistimethate and formed colistin in adult (aged >18 years) critically ill patients. The study was completed prior to the approval by the FDA and EMA of the respective updated dosage guidelines. The ethics committee of each of the 4 institutions in 3 countries (United States, Thailand, and Greece) approved this open-label, nonrandomized study. Informed consent was obtained for all patients. The inclusion and exclusion criteria are described in a report of the interim population PK analysis of the data for the first 105 patients enrolled in the study [16] ; 89 of those patients were not receiving renal replacement therapy (RRT). For the analyses described here, an additional 73 patients not on RRT were included. The demographic characteristics for all 162 non-RRT patients (103 males), summarized as median (range), are as follows: age, 68 years (19-101 years); weight, 60 kg (30-122 kg, 33% being overweight or obese); height, 165 cm (140-193 cm); Acute Physiology and Chronic Health Evaluation II score, 20 (4-43); and estimated creatinine clearance [17] , 57.4 mL/min (5.4-211 mL/min).
Colistin Administration and Sample Collection
Patients received colistimethate intravenously for the treatment of bloodstream infections or pneumonia due to gram-negative organisms that were not susceptible to a number of other antimicrobials [16] . The colistimethate dosage regimen was at the discretion of the physician caring for the patient; the median daily dose of colistin base activity (CBA) was 200 mg (range, 75-600 mg). Eight blood samples were collected at steadystate across a dosage interval on day 3 to 4 of the colistimethate regimen for quantification of plasma concentrations of colistimethate and colistin [16] .
Population Pharmacokinetic Analysis
Population PK analysis, including the full cohort of 162 non-RRT patients, was conducted as described for the interim analysis [16] (see Supplementary Data). In brief, nonlinear mixed-effects modeling was used to analyze the plasma concentration vs time data and identified creatinine clearance (but not body size or any of a number of other investigated variables) as a covariate for the clearance of either colistimethate or colistin. Post hoc plasma concentration vs time profiles for each of the 162 patients were then constructed. This allowed computation for each patient of the plasma colistin C ss,avg , which was achieved from the respective physician-selected daily dose of colistimethate.
Performance of EMA-and FDA-Approved Renally Based Daily Dose Suggestions
From knowledge of the colistin C ss,avg actually achieved with the physician-selected (PS) daily dose of colistimethate in each of the 162 patients, the anticipated C ss,avg for each patient if a daily dose corresponding to the renally based dosing suggestions in the EMA-or FDA-approved product label (PL) had been administered was computed as follows:
The EMA-and FDA-approved daily doses applied in this evaluation are summarized in Table 2 . Where a dose range was approved by the EMA or FDA for a given renal function category, the highest dose in the range was used. In the evaluation of the EMA suggestions, for patients with a creatinine clearance ≥80 mL/min, a daily dose of 360 mg CBA was used since the EMA guidelines state that up to 400 mg may be required. Two approaches were used to evaluate the FDA-approved dose suggestions. The first involved use of the body weight of each of the 162 patients (patient body weight [PBW] approach); for obese patients, the ideal body weight was used [18] . For the second approach (BW80kg), a uniform weight of 80 kg was used. With both approaches used to evaluate the FDA-approved recommendations, the maximum daily dose was 360 mg CBA. For FDA suggestions, calculations for the 2 patients with a creatinine clearance <10 mL/min were conducted using a CBA daily dose of 1 mg/kg. The target attainment rates for the EMA-and FDA-approved daily doses (Table 2 ) to achieve colistin C ss,avg of ≥0.5, ≥1, ≥2, and ≥4 mg/L were determined for each renal function category. The distribution of the 162 patients across the renal function groups is presented in Table 2 ; patients with creatinine clearance <30 mL/min were combined for the evaluation of the performance of the dosing recommendations.
RESULTS
A summary of the plasma C ss,avg of colistin actually achieved with the physician-selected daily maintenance doses administered to Table 3 and Figure 1 ), groups 4a and 4b
were merged into 1 group comprising 32 patients. e For the 2 patients with a creatinine clearance of 5.4 mL/min and 9.2 mL/min, calculations were conducted using a daily dose of CBA of 1 mg/kg as suggested in the FDA-approved product label for patients having creatinine clearance of 10 to <30 mL/min (Table 1) . a Group 4 comprised 30 and 2 patients with creatinine clearance in the ranges 10 to <30 mL/min and <10 mL/min, respectively. See Table 2 for details of the number of patients in each creatinine clearance cluster. b Patient body weight approach: the actual body weight of each of the 162 critically ill patients (ideal body weight for obese patients) was used. Uniform weight of 80 kg approach: a uniform body weight of 80 kg was used.
the 162 critically ill patients with various degrees of kidney function is provided in Table 3 . Also included in the table are the C ss,avg values that would have been achieved with the EMAand FDA-approved daily maintenance dose suggestions. The percentage of patients in each renal function group who achieved various plasma colistin C ss,avg targets with the physician-selected daily doses is shown in Figure 1A . Figure 1 also includes the corresponding plasma colistin C ss,avg attainment rates for the EMA-approved ( panel B) and FDA-approved ( panels C and D) dosing suggestions. The EMA-approved recommendations provided approximately 90% attainment of C ss,avg ≥2 mg/L for patients with creatinine clearance <80 mL/ min. This concentration was attained by only 33.3% of patients with higher renal function. When actual patient body weights were used with the FDA-approved dosing recommendations, attainment rates for a plasma colistin C ss,avg ≥2 mg/L were very low. Only 61.5% of patients with creatinine clearance of 50 to <80 mL/min attained this concentration, but the rate of attainment decreased to 6.3% in patients with the poorest kidney function. When a uniform body weight of 80 kg was applied to the FDA-approved recommendations, the rate of attainment for a C ss,avg ≥2 mg/L was <80% for patients with creatinine clearance <50 mL/min, being only 34.4% in those with creatinine clearance <30 mL/min. Attainment rates for a C ss,avg ≥4 mg/L were <50% with both EMA-and FDAapproved dose recommendations, especially for patients with creatinine clearance >80 mL/min (Figure 1 ).
DISCUSSION
The summary statistics in Table 3 reveal important features of the clinical pharmacology of colistimethate and formed colistin. First, although patients with creatinine clearance ≥80 mL/min were assigned daily doses as high as 360 mg CBA with both the EMA-and FDA-approved dosing recommendations (Table 2) , the colistin C ss,avg was relatively low (Table 3) . Second, with both sets of dosing suggestions, there was up to approximately 12-fold interpatient variability in the plasma colistin C ss,avg across all 4 renal function groups (Table 3 ). These 2 features are consistent with colistimethate being predominantly renally cleared and the efficiency of this elimination pathway impacting the proportion of each colistimethate dose available for conversion to colistin [13, 16, 19] . The extensive interpatient variability across all renal function groups and the narrow therapeutic window of colistin are strongly supportive factors for the use of therapeutic drug monitoring to assist in the optimization of the dosage regimen of colistimethate in individual patients [11, 13, [19] [20] [21] [22] .
The current susceptible breakpoint of the Clinical and Laboratory Standards Institute for Pseudomonas spp. and Acinetobacter spp. is ≤2 mg/L [23] , while the corresponding European Committee on Antimicrobial Susceptibility Testing breakpoints for these species are ≤4 mg/L and ≤2 mg/L, respectively [24] . The analyses conducted here indicate that a plasma colistin C ss,avg of ≥2 mg/L was attainable in approximately 90% of patients with creatinine clearance <80 mL/min with EMA daily doses (Figure 1) . With FDA-approved dosing suggestions, an attainment rate of approximately 90% for C ss,avg of ≥2 mg/L was observed only for patients with a creatinine clearance of 50 to <80 mL/min when using the BW80kg approach (Figure 1) . The FDA-approved daily doses determined using both the PBW and BW80kg approaches for all renal function groups appear acceptable for the reliable attainment of a plasma colistin C ss,avg target of 0.5 mg/L. However, a target of 1 mg/L was not reliably attained with the PBW approach in patients with creatinine clearance <30 mL/min; indeed, in these patients, the BW80kg approach yielded an attainment rate of only 84.4%. The lower plasma colistin C ss,avg values (Table 3 ) and target attainment rates (Figure 1 ) with the FDA-approved recommendations for patients with creatinine clearance <30 mL/min is not surprising. In applying the FDA-approved dosing suggestions, the median daily dose of CBA was 60 mg with the PBW approach and 80 mg with the BW80kg approach. These doses are substantially lower than those approved by the EMA (183 mg for creatinine clearance 10 to <30 mL/min and 117 mg for creatinine clearance <10 mL/min; Table 2 ). The inferior attainment rates for targets of 2 mg/L and higher with the FDA-approved doses determined using both the PBW and BW80kg approaches extended to patients with creatinine clearance 30 to<50 mL/min (Figure 1) .
The dosing suggestions of the EMA and FDA (BW80kg approach) resulted in identical attainment rates for each target concentration in patients with creatinine clearance ≥80 mL/ min; attainment rates were somewhat lower when the PBW approach was applied with the FDA-approved recommendations. The EMA-and FDA-approved doses achieved a colistin C ss,avg of ≥2 mg/L in only approximately 25%-35% of patients with creatinine clearance ≥80 mL/min. In that renal function group, both sets of dosing suggestions attained a colistin C ss,avg of ≥1 mg/L in only approximately 65%-75% of patients ( Figure 1) . Very low attainment rates for a plasma colistin C ss,avg of 4 mg/L occurred in all renal function groups with both the EMA-and FDA-approved dosing suggestions, especially those approved by the FDA. A susceptible breakpoint for colistin of 4 mg/L appears out of reach with both sets of dosing recommendations. Overall, the findings highlight the importance of considering colistin combination therapy for patients with creatinine clearance greater than approximately 80 mL/min, especially for treatment of pneumonia and if the MIC of the infecting organism is ≥1 mg/L [6, 13, 16, [25] [26] [27] .
At initiation of colistimethate therapy, the MIC of the causative organism may not be known. Under these circumstances and given the negative impact on prognosis of inadequate initial antibiotic therapy [28] , a plasma colistin C ss,avg of 2 mg/L may be regarded as an acceptable "target" for antibacterial effect in those patients in whom the probability of attainment is reasonably high (patients with creatinine clearance <80 mL/min receiving EMA-type daily doses; Figure 1 ). However, for such patients, it is also relevant to consider the greater risk of nephrotoxicity as concentrations increase [7, 8] . The increased likelihood of a beneficial antibacterial effect in a patient with a potentially fatal infection must be weighed against an increased risk of colistin-associated nephrotoxicity, which is often mild and usually reversible [29] . Renal function should be carefully monitored during therapy and doses adjusted appropriately [16] .
It is important to consider potential limitations and other factors that may affect this evaluation. The analyses reported here were conducted using data for 162 patients with a wide range of renal function. For some renal function categories, the EMA-and FDA-approved suggestions provide a range of colistimethate daily doses (Table 1) . In these cases, the highest dose in the range was used in the analyses reported here. Thus, the attainment rates for the plasma colistin C ss,avg of 0.5, 1, 2, and 4 mg/L should be regarded as a best-case scenario. It is recognized that in practice, some clinicians may use the full range of doses specified for a particular renal function group, in which case the attainment rates would be lower than shown in Figure 1 . Clearly, the new EMA-and FDAapproved dosing recommendations involve fundamentally different approaches (Table 1 ). The EMA has specified doses for each renal function group in absolute terms (ie, million international units) rather than as body weight-adjusted doses [14] . In contrast, the latter approach has been used in the FDAapproved recommendations wherein doses are expressed as milligrams of CBA per kilogram. In addition, it is indicated that in obese individuals, ideal body weight should be used in determining dose [15] . For the FDA-approved dose recommendations, we evaluated attainment rates using 2 approaches. First, the actual body weight (or ideal body weight) of patients in the population PK study from which the data were derived; the median body weight for these patients was 60 kg. Second, we evaluated a uniform weight of 80 kg as this includes the vast majority of ideal body weights of US men and women [30] and therefore represents a harsh test of body weight-based dosage recommendations. Performance of the FDA-approved recommendations was poorer when a lower weight was used. Finally, the focus of this analysis was on the magnitude of plasma colistin C ss,avg achieved with daily maintenance dosing. The EMA-approved product label includes mention of a loading dose at initiation of therapy. This is an important consideration [19, 31] ; unfortunately, the FDA-approved label is silent on this topic [14, 15] .
In conclusion, our study is the first to assess and compare the recently updated colistimethate renally based dosing recommendations approved by the EMA and FDA. It has revealed fundamental differences between the 2 sets of recommendations, especially for low-body-weight patients with creatinine clearance <50 mL/min in whom the FDA-approved guidelines provide attainment rates for plasma colistin exposure substantially lower than those achieved with EMA-approved dosing suggestions. This aspect deserves careful consideration by clinicians and regulators. For patients with creatinine clearance ≥80 mL/min, dosing based on both suggestions was unable to achieve attainment rates >80% for plasma colistin concentrations of ≥1 mg/L. This highlights the potential role of combination regimens for patients in this category. The very wide interindividual variability in plasma colistin concentrations achieved at a given daily maintenance dose points to the need for a prospective evaluation of therapeutic drug monitoring as an aid to individualization of dosage regimens. Finally, the results will assist in current deliberations on clinical breakpoints for colistin.
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